NeoPharm Co. Ltd. (092730.KQ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	148.4B	132.2B	119.0B	97.1B	85.0B
Cost of Revenue	51.0B	47.5B	45.0B	33.0B	27.8B
Gross Profit	97.3B	84.7B	74.0B	64.2B	57.3B
Operating Expenses
R&D Expense	2.4B	3.3B	3.4B	2.6B	2.9B
SG&A Expense	32.1B	40.1B	33.5B	36.3B	33.0B
General & Admin Expense	1.7B	2.0B	2.1B	12.3B	11.1B
Selling & Marketing Expense	30.4B	38.1B	31.4B	23.9B	21.9B
Other Expenses	31.2B	12.5B	12.5B	78.4M	—
Total Operating Expenses	64.9B	55.9B	49.4B	38.9B	35.8B
Cost and Expenses	115.9B	103.4B	94.4B	71.8B	63.6B
Operating Income (EBIT)	32.5B	28.8B	24.7B	25.3B	21.4B
Non-Operating
Interest Income	3.6B	3.8B	4.2B	4.6B	2.1B
Interest Expense	53.4M	39.4M	40.8M	21.3M	8.8M
Net Interest Income	3.5B	3.7B	4.1B	4.6B	2.1B
Other Non-Op Income/Expense	6.7B	3.5B	5.6B	4.1B	1.9B
Non-Operating Income (excl Interest)	(5.5B)	—	(5.6B)	(4.1B)	(1.9B)
EBT (Pre-Tax Income)	39.1B	32.3B	30.2B	29.4B	23.3B
Income Tax Expense	8.5B	4.4B	7.1B	6.2B	6.3B
Bottom Line
Net Income	30.6B	27.9B	23.1B	23.2B	17.0B
Earnings from Cont. Ops	30.6B	27.9B	23.1B	23.2B	17.0B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	30.6B	27.9B	23.1B	23.2B	17.0B
Per Share
Basic EPS	₩1,947	₩1,779	₩1,474	₩1,484	₩1,089
Diluted EPS	₩1,947	₩1,779	₩1,474	₩1,484	₩1,089
Revenue Per Share	₩9,258	₩8,460	₩7,609	₩12,416	₩10,872
Shares
Basic Shares Outstanding	16.0M	15.6M	15.6M	7.8M	7.8M
Diluted Shares Outstanding	16.0M	15.6M	15.6M	7.8M	7.8M
Profitability Metrics
EBITDA	40.1B	31.9B	33.3B	31.0B	24.9B
D&A	3.3B	3.1B	3.1B	1.7B	1.6B
EBIT	36.7B	28.8B	30.2B	29.4B	23.3B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026